-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the US Food and Drug Administration Board announced its antimicrobial Drugs Advisory Committee (AMDAC) upcoming meeting to discuss the application of molnupiravir Merck and Ridgeback's Emergency Use Authorization (EUA) of, molnupiravir is for the treatment of COVID-19 Of research antiviral drugs
Manage COVID-19
On November 30, the advisory committee will hold a meeting to discuss the decision to support the use of molnupiravir to treat patients with mild to moderate COVID-19
On November 30, the advisory committee will hold a meeting to discuss the decision to support the use of molnupiravir to treat patients with mild to moderate COVID-19
FDA 's Center for Drug Evaluation and Research, MD, Patrizia Cavazzoni said: "FDA is evaluating the safety and efficacy data submitted by Merck and Ridgeback in its emergency use authorization request, molnupiravir for a new diagnostic out COVID-19 New oral treatments for people at high risk of infection
FDA diagnoses infection
According to the FDA's judgment, the agency can convene an advisory committee to solicit independent external experts' advice on a variety of complex scientific, technical, and policy issues
The meeting is scheduled as soon as possible after the company submits the EUA request
FDA intends to provide the public with background materials for the AMDAC meeting, including the meeting agenda and committee roster, no later than two working days before the meeting
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https://
